Three years after its founding, Reed Jobs' oncology venture firm Yosemite has raised a $350 million second fund and grown to nearly 25 portfolio companies — a pace that surprised even its founder. Built on the premise that philanthropy and capital could be fused to pull cancer treatments directly from university laboratories, Yosemite now operates at a moment when pharmaceutical patent cliffs, record industry cash reserves, and the maturation of AI in drug discovery have aligned in ways that make previously undruggable genes feel, for the first time, within reach. The firm's quiet urgency is n
TechCrunch
· Jul 12, 2026
· technology
· 10 min read
High
Sourcing: Verified
Reed Jobs's Yosemite VC Targets 'Undruggable' Cancer Genes as AI Transforms Drug Discovery
The work targets cancer treatment advancement affecting millions; hepatitis B affects 250M+ people globally; pancreatic cancer survival improvements noted (12 to 24 months).
◉
Science & Space
7155 related articles
NASA Launches Artemis II: Four Astronauts Head to Moon in Historic Mis…
Devdiscourse · 100% match
NASA study finds Earth microbes could survive on Moon's South Pole, co…
Texas Public Radio | TPR · 99% match
Blue Origin Probed Over Rocket Failure as Mars Rover Finds Organic Com…
Devdiscourse · 99% match
Israeli radiation vest shows promise for safer deep-space missions
jns.org · 99% match
Starship's Raw Power Masks Mars Challenge: Orbital Refueling Still Unp…
Space Daily · 99% match
Related Coverage
News-Medical · Aug 27
Dysfunctional brain cells linked to age-related cognitive decline in landmark study
Research reveals that faulty oligodendrocytes with reduced NRF2 expression contribute to cognitive aging through abnorma…
The Times of India · Aug 27 Scientists reveal 'junk' DNA acts as chromosome barcode during reproductionResearchers discovered that satellite DNA, long dismissed as evolutionary clutter, functions as a barcode enabling chrom…
News-Medical · Aug 27 Men reject traditional diets as restrictive, female-focused: studyA UK study finds men avoid weight-loss programs perceived as restrictive and female-oriented, with 70% of English men ov…
News-Medical · Aug 27 Maternal immune response to UTI, not bacteria, drives preterm birth riskNew research shows maternal immune response to urinary tract infections, not the bacteria itself, drives preterm birth r…
Bias & Framing
⚖
Article presents favorable profile of Reed Jobs and Yosemite VC with minimal critical examination, using personal charm details and optimistic framing around AI-driven drug discovery.
Bias Direction
center-right
Confidence
MED
Hagiographic profile framing that emphasizes the subject's likability, ambition, and success while minimizing scrutiny. Opens with character-building anecdotes and positions Jobs as humble despite his privileged background.
easy to like
motormouthed, self-deprecating
clearly loves his work
not uptight
ambitious about turning Yosemite into a serious player
blockbuster drugs
incredible tract
Critical analysis of VC concentration in biotech and wealth inequality
Perspectives from competing biotech firms or researchers
Discussion of failed Yosemite portfolio companies or setbacks
Voices questioning AI's actual impact on drug discovery timelines
Analysis of whether philanthropy-VC hybrid model serves public interest or primarily wealthy investors
Regulatory or ethical concerns about accelerated drug development
Geopolitical Impact
🌎
Private biotech VC firm leveraging AI for cancer drug discovery poses minimal geopolitical risk; primarily a commercial innovation story with potential healthcare benefits.
Escalation Risk
low
Confidence
MED
United States
Global pharmaceutical market
Consolidation of drug discovery capabilities in private US venture capital, potentially shifting pharmaceutical innovation from traditional Big Pharma to nimble biotech startups; strengthens US biotech ecosystem competitiveness.
Similar to 1980s-90s biotech revolution when venture capital democratized drug discovery away from established pharmaceutical monopolies, now accelerated by AI.
Economic Lens
📈
AI-driven oncology VC firm Yosemite raises $350M to develop novel cancer treatments targeting previously undruggable genes, signaling accelerating biotech innovation and patent cliff opportunities.
Market Signal
bullish
Confidence
HIGH
Biotechnology
Pharmaceutical Manufacturing
Artificial Intelligence/Machine Learning
Healthcare Services
Venture Capital
Academic Research
Potential long-term benefits through access to novel cancer treatments targeting previously untreatable genes (p53, KRAS); near-term impact limited as therapies remain in development/clinical phases; healthcare costs may eventually decrease if treatments prove effective and reduce need for alternative interventions.
Likely increased FDA focus on accelerated approval pathways for AI-discovered oncology drugs; potential regulatory framework updates for AI-assisted drug discovery; possible patent policy discussions around gene targets; increased government interest in supporting biotech innovation through grants and partnerships.